NovoCure
NVCR
NVCR
293 hedge funds and large institutions have $5.38B invested in NovoCure in 2023 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 85 increasing their positions, 97 reducing their positions, and 53 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
293
Holders Change
-10
Holders Change %
-3.3%
% of All Funds
4.69%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
45
Increased
85
Reduced
97
Closed
53
Calls
$151M
Puts
$57.8M
Net Calls
+$93.4M
Net Calls Change
+$153M
Top Buyers
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$92.2M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$70.7M |
| 3 |
BlackRock
New York
|
+$43.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$32.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.3M |
Top Sellers
| 1 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$18.5M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$18.2M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$15.7M |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$8.02M |
| 5 |
Goldman Sachs
New York
|
-$7.22M |
